Name: Recombinant Anti-CD64 x Anti-HIV-1 gp41 Bispecific Antibody (scFv-IgG)
SKU: BSSG-127
Rating: 5 (1 reviews)

Recombinant Anti-CD64 x Anti-HIV-1 gp41 Bispecific Antibody (scFv-IgG) is formed by an IgG and two scFv fragments. The scFvs from an anti-CD64 antibody variable domain are respectively connected to the N terminus of the anti-HIV-1 gp41 IgG heavy chains or light chains to form scFv-(H)IgG or scFv-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of HIV-1 infection, AIDS therapy.

Datasheet INQUIRY

Specifications

Targets

CD64 & HIV-1 gp41

Type

scFv-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

HIV-1 infection, AIDS

Host Animal 1

Mouse

Host Animal 2

Mouse

Targets

Target 1

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Target 2

HIV-1 gp41

Gene ID

155971

UniProt ID

Q0H5Z9

Alternative Names

ENV; gp160; Envelope glycoprotein 120; envelope glycoprotein; Envelope surface glycoprotein gp160, precursor; hypothetical protein; Envelope surface glycoprotein gp120; Envelope transmembrane domain; human immunodeficiency virus type 1; human immunodeficiency virus type 1 gp120; human immunodeficiency virus type 1 glycoprotein 120; gp41; GP41; glycoprotein 41

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD64 x Anti-HIV-1 gp41 Bispecific Antibody (scFv-IgG) (BSSG-127). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD64 x Anti-HIV-1 gp41 Bispecific Antibody (scFv-IgG) (CAT#: BSSG-127)

Specifications

Targets

Customer Reviews and Q&As